🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ The Pharmacist's Role: How Community Pharmacies in Ireland and the UK Are Adapting as Patients Bypass High-Street Stores for Direct Delivery ◆ GLP-1 Therapeutics and Clinical Research Updates: Brain Reward Mapping, Oral Small Molecules, and Triple-Agonist Horizons ◆ Rinn Pharma & Biopharma Joins NordicPharmaTrain Network to Accelerate European Research & Advanced Manufacturing ◆
Updated 13 Sep 2026 · EMA CTIS official data

Clinical Trials in Slovakia

← All EU trials

The most recently authorised clinical trials across the European Union - drawn live from the European Medicines Agency's Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation. Searchable by country, phase, sponsor and condition.

20
Recent authorisations
13
Phase III trials
Slovakia
Selected country
Showing 20 trials
Phase II Immune System Diseases Authorised 09/09/2026

A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study

Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
33 participants planned
Germany · Italy · Slovakia · Spain
2026-526241-98-00 on CTIS ↗
Phase II Immune System Diseases Authorised 08/09/2026

A Phase 2, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous Administered by Prefilled Syringe in Adult Participants with Sjogren’s Disease-Associated Sensorimotor or Sensory Polyneuropathy

Sjogren’s Disease-Associated Sensorimotor Polyneuropathy (SMPN) or Sensory Polyneuropathy (SPN)
Argenx
34 participants planned
Germany · Lithuania · Portugal · Slovakia · Hungary · Spain · Belgium · France
2026-526218-10-00 on CTIS ↗
Phase II Nervous System Diseases Authorised 07/09/2026

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia

Tardive Dyskinesia
Neurocrine Biosciences Inc.
15 participants planned
Bulgaria · Slovakia · Czechia
2025-524104-30-00 on CTIS ↗
Phase III Immune System Diseases Authorised 02/09/2026

A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy

Immune system diseases
Sanofi-Aventis Recherche & Developpement
338 participants planned
Belgium · Czechia · Hungary · Sweden · Lithuania · Croatia · Netherlands · Slovakia · Poland · Austria · Norway · France · Italy · Bulgaria · Spain · Germany · Romania · Slovenia · Estonia · Portugal · Greece · Denmark
2026-525913-30-00 on CTIS ↗
Phase II Skin and Connective Tissue Diseases Authorised 01/09/2026

A multicenter, prospective, randomized, placebo and non-surgical standard of care (NSSOC) controlled study, performed to evaluate the safety and efficacy of EscharEx and its placebo (gel vehicle) compared to NSSOC in participants with Venous Leg Ulcers (VLU)

Venous Leg Ulcer (VLU)
Mediwound Ltd.
35 participants planned
Czechia · Slovakia
2026-526070-16-00 on CTIS ↗
Phase II Nutritional and Metabolic Diseases Authorised 31/08/2026

Efficacy and safety of once-weekly subcutaneous UBT251 in participants with type 2 diabetes – a dose-finding study

Type 2 diabetes (T2D)
Novo Nordisk A/S
175 participants planned
Spain · Hungary · Romania · Slovakia · Poland · Germany
2026-525465-42-00 on CTIS ↗
Phase III Neoplasms Authorised 21/08/2026

A Multicenter, Randomized, Double-Blind, Double-Dummy, Phase III Study to Evaluate the Efficacy and Safety of Letrozole SIE Compared to Femara® (both in Combination with the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women with HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast Cancer (SIE-3)

​​HR-positive, HER2-negative, inoperable locally advanced or metastatic breast cancer​
Laboratorios Farmaceuticos Rovi S.A.
97 participants planned
Romania · Spain · Bulgaria · Czechia · Latvia · Poland · Croatia · Slovakia
2025-524846-85-00 on CTIS ↗
Phase III Eye Diseases Authorised 17/08/2026

A Randomized, Double-masked, Comparative Clinical Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 938 8 mg Versus EYLEA® HD (Aflibercept) Delivered via Intravitreal Injection in Participants with Neovascular Age-related Macular Degeneration

Neovascular Age-related Macular Degeneration (nAMD)
Amgen Inc.
255 participants planned
Slovakia · Latvia · Czechia · Poland · Spain · Hungary · Lithuania
2025-523500-72-00 on CTIS ↗
Phase II Cardiovascular Diseases Authorised 14/08/2026

A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)

heart failure
Cardurion Pharmaceuticals Inc.
369 participants planned
Latvia · Slovakia · Lithuania · Hungary · Italy · Netherlands · Spain · Poland · Bulgaria · Czechia
2025-525033-31-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 03/08/2026

A Randomized, Double-blind, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron and Dapagliflozin in Combination, Compared with Elecoglipron Alone and Dapagliflozin Alone, in Adults with Type 2 Diabetes Mellitus (Eluminate-5)

type 2 diabetes mellitus
AstraZeneca AB
360 participants planned
Slovakia · Poland · Czechia · Germany · Hungary · Greece · Denmark
2025-523941-81-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease

Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
194 participants planned
Norway · Romania · Austria · Italy · Slovakia · Germany · Hungary · Netherlands · Belgium · France · Portugal · Czechia · Poland · Spain · Greece
2026-525922-39-00 on CTIS ↗
Phase III Immune System Diseases Authorised 03/08/2026

A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis

Moderately to Severely Active Ulcerative Colitis
Janssen Cilag International
302 participants planned
France · Bulgaria · Romania · Slovakia · Norway · Denmark · Greece · Italy · Austria · Poland · Netherlands · Czechia · Germany · Belgium · Spain · Hungary · Portugal
2026-525923-26-00 on CTIS ↗
Phase III Cardiovascular Diseases Authorised 29/07/2026

A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

Heart failure with preserved ejection fraction (HFpEF) and heart failure with mildly reduced ejection fraction (HFmrEF); on background SGLT2i.
AstraZeneca AB
2343 participants planned
Spain · Hungary · Germany · Poland · Italy · Bulgaria · Netherlands · Austria · Romania · Sweden · France · Greece · Slovakia · Czechia
2026-526304-79-00 on CTIS ↗
Phase III Nutritional and Metabolic Diseases Authorised 27/07/2026

A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes

Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
1140 participants planned
Greece · Portugal · France · Slovakia · Bulgaria · Netherlands · Romania · Italy · Austria · Poland · Hungary · Spain · Czechia · Belgium
2025-522488-14-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 20/07/2026

A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease

Huntington’s Disease
Novartis Pharma AG
368 participants planned
Norway · Poland · Spain · Sweden · Bulgaria · Netherlands · Finland · Portugal · Austria · Italy · Greece · Ireland · Czechia · France · Romania · Belgium · Germany · Denmark · Slovakia · Hungary
2025-522227-99-00 on CTIS ↗
Phase III Female Urogenital Diseases and Pregnancy Complications Authorised 14/07/2026

A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis

Focal segmental glomerulosclerosis (FSGS)
Apellis Pharmaceuticals Inc.
97 participants planned
France · Portugal · Spain · Slovakia · Italy · Germany · Poland
2025-524448-36-00 on CTIS ↗
Phase III Respiratory Tract Diseases Authorised 06/07/2026

A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype

Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
550 participants planned
Germany · Romania · Greece · Norway · Netherlands · Poland · Lithuania · Czechia · Slovakia · Spain
2024-518213-25-00 on CTIS ↗
Phase III Immune System Diseases Authorised 29/06/2026

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care

Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease
Merck Healthcare KGaA
54 participants planned
Spain · Belgium · France · Germany · Slovakia · Romania · Bulgaria · Italy · Poland · Greece
2025-523871-44-00 on CTIS ↗
Phase III Nervous System Diseases Authorised 22/06/2026

A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis

Non-active Secondary Progressive Multiple Sclerosis (SPMS)
Zenas Biopharma (USA) LLC
486 participants planned
Germany · Bulgaria · Netherlands · Sweden · Portugal · Croatia · Italy · Austria · Spain · Poland · France · Denmark · Hungary · Romania · Estonia · Slovakia · Belgium · Czechia · Norway · Lithuania · Greece
2025-524322-18-00 on CTIS ↗
Phase II Digestive System Diseases Authorised 16/06/2026

A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease

Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
228 participants planned
Croatia · Poland · Austria · Czechia · Italy · Slovakia · Bulgaria · Greece · Belgium · Spain · Hungary · Germany · Lithuania · France · Romania
2025-524640-35-00 on CTIS ↗
No trials match your search.
Cite this page

Priya Life Science (2026). EU Clinical Trials Tracker. Available at: https://priyalifescience.com/clinical-trials-europe/country/slovakia (Accessed: 13 September 2026).

Embed this data ↗

Source: Clinical Trials Information System (CTIS), European Medicines Agency - trials authorised under the EU Clinical Trials Regulation (Regulation 536/2014), showing the most recent EU authorisation decisions, refreshed daily. Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See our Ireland Clinical Trials Tracker. For approved medicines, see the EMA Approvals Tracker. See who's running these trials in our Company Directory, or compare pay across these markets in the EU Salary Guide.